Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib Added to Chemoradiotherapy for Unresectable Stage III NSCLC
NCT01386385Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2011
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Arm I (RT, veliparib, carboplatin, paclitaxel) with Arm II (3D-CRT, placebo, carboplatin, paclitaxel) (2 arms). Primary endpoints: Maximum Tolerated Dose at 9 weeks and Progression-Free Survival up to 5 years. Started Jun 2011; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01386385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386385.